Flow immunocytochemistry of marker expression in cells from body cavity fluids

Cytometry Part A

Volumn 77, Issue 2, 2010, Pages 132-143

  Krishan, Awtar ^a   Ganjei Azar, Parvin ^a   Hamelik, Ronald ^a   Sharma, Deepti ^a   Reis, Isildinha ^a   Nadji, Mehrdad ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cells in body cavity fluids; Flow cytometry; Immunocytochemistry; Tumor associated markers

Indexed keywords

DNA; TUMOR MARKER;

ANEUPLOIDY; ARTICLE; ASCITES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MALE; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PLEURA EFFUSION; SENSITIVITY AND SPECIFICITY;

ANEUPLOIDY; ASCITES; CELL SEPARATION; DNA, NEOPLASM; FALSE NEGATIVE REACTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; PLEURAL EFFUSION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77249113262     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20824     Document Type: Article

References (32)

1. Motherby H, Nadjari B, Friegel P, Kohaus J, Ramp U, Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999;20:350-357.
2. Ganjei-Azar P, Jorda M, Warner B, Gomez-Fernandez C. Is there still a role for conventional cytology in body cavity effusions? Acta Cytol 2004;48:653.
3. Evans DA, Thornthwaite JT, Ng AB, Sugarbaker EV. DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy. Anal Quant Cytol1983;5:19-27.
4. Lovecchio JL, Budman DR, Susin M, Grueneberg D, Fenton AN. Flow cytometry of peritoneal washings in gynecologic neoplasia. Obstet Gynecol 1986;67:675-679.
5. Stonesifer KJ, Xiang JH, Wilkinson EJ, Benson NA, Braylan RC. Flow cytometric analysis and cytopathologyofbodycavityfluids. Acta Cytol1987;31:125-130.
6. Krishan A, HamelikRM, Ganjei-Azar P, Jorda M, Reis IM, Nadji M. Detection oftumor cells in body cavity fluids by flow cytometric and immunocytochemical analysis. Diagn Cytopathol 2006;34:528-541.
7. Hedley DW, Philips J, Rugg CA, Taylor IW. Measurement of cellular DNA content as an adjunct to diagnostic cytology in malignant effusions. Eur J Cancer Clin Oncol 1984;20:749-752.
8. Jones MA, Hitchcox S, D'Ascanio P, Papillo J, Tarraza HM. Flow cytometric DNA analysis versus cytology in the evaluation of peritoneal fluids. Gynecol Oncol 1991;43:226-232.
9. Both CT, de Mattos AA, Neumann J, Reis MD. Flow cytometry in the diagnosis of peritoneal carcinomatosis. Am J Gastroenterol 2001;96:1605-1609.
10. Kummar S, Fogarasi M, Canova A, Mota A, Ciesielski T. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br J Cancer 2002;86:1884-1887.
11. Jorda M, Gomez-Fernandez C, Ganjei-Azar P. The limited immunochemical panel of EMA and calretinin distinguishes adenocarcinomas from mesothelial proliferations in body cavity fluids. Acta Cytol 2000;44:854-855.
12. Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J 2008;22:966-981.
13. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to bodyfluids. Am J Clin Pathol 2002;117:745-750.
14. Ordonez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 2005;36:1163-1167.
15. Wu M, Szporn AH, Zhang D, Wasserman P, Gan L, Miller L, Burstein DE. Cytology applications ofp63 and TTF-1 immunostaining in differential diagnosis oflung cancers. Diagn Cytopathol 2005;33:223-227.
16. Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously stained pap-stainedcytologicmaterial. ModPathol2006;19:1117-1123.
17. Lee JS, Lee MC, Park CS, Juhng SW. Diagnostic value of p53 protein and flow cytometric DNA analysis in the study of serous effusions. Acta Cytol 1997;41:1719-1725.
18. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks ofmalignant effusions and FNAspecimens. Diagn Cytopathol 1994;10:130-134.
19. Davidson B. Malignant effusions: From diagnosis to biology. Diagn Cytopathol 2004;31:246-254.
20. Davidson B, Dong HP, Berner A, Christensen J, Nielsen S, Johansen P, Bryne M,Asschenfeldt P, Risberg B. Detection of malignant epithelial cells in effusions usingflow cytometric immunophenotyping: An analysis of 92 cases. Am J Clin Pathol 2002;118:85-92.
21. Sigstad E, Dong HP, Davidson B, Berner A, Tierens A, Risberg B. The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens. Diagn Cytopathol 2004;31:159-163.
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
23. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH,Goulet R Jr, Badve S, Nakshatri H. CD44+/CD24" breast cancer cells exhibitenhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59-71.
24. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M,Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS,Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
25. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+CD24" and CD133+ cells with cancerstem cell characteristics. Breast Cancer Res 2008;10:R10-25.
26. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol1975;66:188-193.
27. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest 2003;83:1427-1435.
28. Zhou X-H, ObuchowskiNA, McClish DK. StasticalMethodsinDiagnosticMedicine. New York: Wiley; 2002.
29. O'Leary TJ. Flow cytometry in diagnostic cytology. Diagn Cytopathol 1998;18:41-46.
30. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: A useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol2007;31:1139-1148.
31. Jang KY, Kang MJ, Lee DG, Chung MJ. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001;23:400-404.
32. Dong HP, Holth A, Berner A, Davidson B, Risberg B. Flow cytometric immunophenotyping of epithelial cancer cells in effusions-technical considerations and pitfalls. Cytometry B Clin Cytom 2007;72B:332-343.